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ABSTRACT
Inhibitors of mitochondrial respiration and ATP synthesis may promote the selective 
killing of respiration-competent cancer cells that are critical for tumor progression. 
We previously reported that CADD522, a small molecule inhibitor of the RUNX2 
transcription factor, has potential for breast cancer treatment. In the current study, 
we show that CADD522 inhibits mitochondrial oxidative phosphorylation by decreasing 
the mitochondrial oxygen consumption rate (OCR) and ATP production in human breast 
cancer cells in a RUNX2-independent manner. The enzyme activity of mitochondrial 
ATP synthase was inhibited by CADD522 treatment. Importantly, results from cellular 
thermal shift assays that detect drug-induced protein stabilization revealed that CADD522 
interacts with both α and β subunits of the F1-ATP synthase complex. Differential scanning 
fluorimetry also demonstrated interaction of α subunits of the F1-ATP synthase to 
CADD522. These results suggest that CADD522 might target the enzymatic F1 subunits in 
the ATP synthase complex. CADD522 increased the levels of intracellular reactive oxygen 
species (ROS), which was prevented by MitoQ, a mitochondria-targeted antioxidant, 
suggesting that cancer cells exposed to CADD522 may elevate ROS from mitochondria. 
CADD522-increased mitochondrial ROS levels were enhanced by exogenously added 
pro-oxidants such as hydrogen peroxide or tert-butyl hydroperoxide. Conversely, 
CADD522-mediated cell growth inhibition was blocked by N-acetyl-l-cysteine, a general 
ROS scavenger. Therefore, CADD522 may exert its antitumor activity by increasing 
mitochondrial driven cellular ROS levels. Collectively, our data suggest in vitro proof-of-
concept that supports inhibition of mitochondrial ATP synthase and ROS generation as 
contributors to the effectiveness of CADD522 in suppression of tumor growth.
INTRODUCTION
Breast cancer (BC) is the second leading cause of 
cancer-related deaths among women, but early detection 
and improved treatment options have led to increased 
patient survival. Despite recent advances in treatment, 
however, its clinical management still remains a challenge 
[1]. Therefore, development of new strategies that increase 
the therapeutic index of chemotherapeutics and decrease 
the incidence of the disease are needed. Chemotherapy, 
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radiation and hormonal therapy are useful in treating 
advanced BC [2], however, targeting cancer metabolism 
has become an attractive therapeutic option [3–6].
Alterations of mitochondrial function are associated 
with development of several types of cancer [7]. In contrast 
to Warburg’s first observations, maintaining functional 
mitochondria appears to be key for cancer cell survival 
and proliferation [8]. Mitochondria are still functional in 
glycolytic cancer cells (with high Glut-1 and phospho-
Akt expression) producing abundant amounts of ATP [9]. 
Recent reports suggest that inhibitors of mitochondrial 
oxidative phosphorylation (OXPHOS) could promote the 
selective eradication of stem-like tumor cells due to their 
preferential sensitivity to mitochondrial reactive oxygen 
species (ROS) [10]. Functional mitochondria that are 
respiration competent are thus critical for tumorigenesis 
and targeting mitochondrial metabolism may be a novel 
and successful therapeutic strategy for cancer [7].
Under physiological conditions, mitochondrial 
membrane proton pumps (i.e., electron transport chain, 
ETC) generate an electrochemical proton gradient, the 
main component of which is mitochondrial membrane 
potential (MMP, ∆Ψm). ATP synthase acts as a sensor of 
glucose supply by utilizing a proton gradient generated 
by the ETC from electron donors that ultimately originate 
from glucose-derived pyruvate. The protonmotive force 
(∆p) is used by ATP synthase to produce ATP to meet 
the energy needs of the cell. Reactive oxygen species 
(ROS) are primarily generated from complex I and III in 
mitochondria, but increased ROS is often due to blockade 
of complex IV [11, 12] or ATP synthase [13–15]. ATP 
synthase inhibition results in ∆Ψm elevation, leading to 
increased electron leak to superoxide [15]. Mitochondrial 
ROS are important for cell proliferation and tumor growth 
[16], but also can induce DNA damage, protein oxidation 
and lipid peroxidation [15, 17], potentially initiating 
cell death [18, 19]. Intrinsic MMP (∆Ψm) in cancer 
cells generally correlates with tumor development and 
progression, and invasive cellular behavior [20].
Numerous molecules that act on mitochondria are 
currently used or being tested in clinical trials [21], and 
many therapeutics that target mitochondria reduce ATP 
levels and increase ROS production [15, 22–28]. For 
example, tamoxifen is widely used in adjuvant therapy 
for all stages of BC. It inhibits complexes III and IV, 
inducing MMP (∆Ψm) collapse [29] and increased ROS 
production [30]. In addition, it has been reported that 
the mitochondrial Fo/F1-ATP synthase is a target for 
dietary phytochemicals such as resveratrol, genistein, 
and epigallocatechin [14], which can reduce ATP levels. 
Resveratrol targets Complexes I and II, but it also targets 
the F1 domain of ATP synthase, resulting in a non-
competitive inhibition of F1-ATP synthase activity [31]. 
Therefore, inhibiting mitochondria may be a rational 
therapeutic approach, since BC cells are especially 
sensitive to ROS-mediated oxidative stress [23].
ATP synthase is reported to be upregulated in 
breast tumors. Among five subunits in the hydrophilic 
F1-portion of the mitochondrial H+-ATP synthase, the α 
subunits are correlated with larger, poorly differentiated 
and high stage tumors [32, 33]. However, one report 
suggests no significant difference in the expression levels 
of β-F1-ATP synthase in BC tissues when compared with 
normal breast [34]. Nonetheless, reduced expression of the 
catalytic β subunit (β-F1-ATP synthase) is linked to cancer 
progression [35–37] and resistance of cancer cells to 
standard anticancer therapies [38–41]. β-F1-ATP synthase 
levels are also inversely correlated with aerobic glycolysis 
in cancer cells [42].
Most ATP synthase inhibitors often demonstrate 
unacceptable in vivo toxicity [43]. However, some of them 
still have potential to be used as anticancer agents. For 
example, oligomycin A inhibits the proton-translocating 
Fo-portion of the ATP synthase, and also affects the 
F1-portion at high concentration [44, 45]. Oligomycin 
dramatically attenuates BC metastatic seeding in the 
lungs, which demonstrates the functional importance of 
OXPHOS in metastasis and highlights its potential as a 
therapeutic target to prevent metastatic spread in patients 
with BC [46]. Aurovertin B inhibits the activity of ATP 
synthase by interacting with the β subunit of the F1-
ATP synthase and limits proliferation of BC cells with 
little influence on the normal mammary epithelial cells 
(MCF-10A) [32]. Citreoviridin, which is in the same 
class as aurovertin, targets the β subunit of the F1-ATP 
synthase [47, 48], inhibits the growth and proliferation 
of BC cells as well as lung adenocarcinoma cells [49, 
50]. Rhodamine123 inhibits BC colony formation, which 
was reported to be due to inhibition of the FoF1-ATP 
synthase enzyme complex leading to ATP depletion [51]. 
Benzodiazepine (Bz-423) directly inhibits the F1-ATP 
synthase and initiates apoptosis by increasing generation 
of superoxide (O2
–) from the respiratory chain within 
mitochondria [43].
We previously reported that the transcription 
factor runt-related transcription factor 2 (RUNX2) 
promotes glycolytic switching in BC cells by increasing 
expression of genes regulating glycolytic pathways 
[52]. RUNX2 decreases pyruvate dehydrogenase (PDH) 
activity but RUNX2 KD increases mitochondrial oxygen 
consumption rate (OCR) by increasing the activity of 
PDH, a rate limiting step for entry into the TCA cycle 
at the branch point for pyruvate utilization. These 
findings led us to hypothesize that targeting RUNX2 
might inhibit BC growth and/or progression by reversing 
tumor cell dependence on glycolysis. In our effort to find 
small molecules that target RUNX2 by interfering with 
RUNX2 binding to the specific DNA sequences, we used 
Computer-Assisted Drug Design (CADD) [52, 53]. Based 
on this approach, CADD522 (Supplementary Figure 2, 
left) was identified as a potent inhibitor of RUNX2-DNA 
binding [52, 53].
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CADD522 inhibited the in vitro DNA binding 
activity of RUNX2 at nanomolar concentrations (IC50 
≅ 10 nM) [53] and inhibited BC growth and metastasis 
in both in vitro and in vivo models by specifically 
downregulating RUNX2-mediated transcription of 
downstream targets [52]. Since CADD522 suppressed 
RUNX2-mediated Glut-1 expression as well as glucose 
uptake and utilization [52], we initially hypothesized that 
CADD522 could restore the mitochondrial metabolic 
pathways that RUNX2 repressed. Unexpectedly, 
however, we observed that CADD522 directly targeted 
mitochondrial oxidative phosphorylation, decreasing 
mitochondrial OCR and ATP production in BC cells. 
CADD522 repressed FoF1-ATP synthase activity but 
increased ROS levels in a RUNX2-independent manner. 
Therefore, CADD522 may demonstrate therapeutic 
potential for BC by targeting mitochondria.
RESULTS
Inhibition of mitochondrial respiration
Mitochondrial respiration is the most important 
generator of cellular energy through the process of energy 
conversion of carbon substrates into ATP. Previously, 
we showed that loss of RUNX2 by gene knockdown 
(KD) increases OCR [54]. Our extended studies now 
demonstrate that ATP levels and mitochondrial ATP 
synthase activity significantly increase in Hs578t cells 
after RUNX2 KD compared to non-targeting control 
(NTC) (Supplementary Figure 1A and 1B). The increase 
was observed in Galactose M, a condition where 
cellular ATP production is dependent on mitochondrial 
OXPHOS rather than glycolysis, but not in Serum-
Free Glucose M. Mitochondrial Complex I activity also 
increased in RUNX2 KD cells compared to NTC cells 
(Supplementary Figure 1C). In contrast to a slight but 
significant increase of mitochondrial mass in RUNX2 
KD cells (Supplementary Figure 1D), no significant 
difference in MMP (∆Ψm) was observed between NTC 
and RUNX2 KD cells (Supplementary Figure 1E). In 
addition, intracellular and mitochondrial ROS levels 
determined by DCF and MitoSox fluorescence intensity, 
respectively, as well as the H2O2 Luc intensity increased in 
Hs578t cells with RUNX2 KD (Supplementary Figure 1F 
and 1G). Collectively, these findings indicate that RUNX2 
KD results in activation of mitochondrial ATP synthase 
activity, which may lead to increases in respiration [54], 
ATP production and ROS generation.
These findings led us to hypothesize that CADD522 
(Supplementary Figure 2A, left), a RUNX2-DNA binding 
inhibitor, would promote mitochondrial OCR and ATP 
synthesis in BC cells expressing RUNX2. To test this 
hypothesis in this study, we first determined the kinetics 
of the acute (immediate) OCR changes in T47D-Empty 
and -RUNX2 overexpressing cells by exposing cells to 
CADD522 at the time of assay. Increasing concentrations 
of CADD522 (0~200 µM) were directly injected into 
port A of the XF analyzer. In parallel, oligomycin A 
was injected in separate wells as a positive control. 
Unexpectedly, CADD522 reduced the respiratory capacity 
of both T47D-Empty and T47D-RUNX2 cells in a 
concentration-dependent manner (Figure 1A). Oligomycin 
A had no significant influence on the FCCP-induced 
maximal respiratory capacity (MRC) compared to the 
vehicle control (Control, 0.1% DMSO).
Next, we treated cells with CADD522 (50 µM) for 
72 hr and determined the OCR without further addition 
of CADD522 during the assay. Mitochondrial respiration 
parameters-baseline OCR (BL), maximal respiratory 
capacity (MRC), reserve capacity (RC), ATP production-
linked OCR (AP), and proton leak-linked OCR (PL) 
(Supplementary Figure 2A, right) were measured by 
the addition of mitochondrial OXPHOS inhibitors such 
as oligomycin A (O) or antimycin A (AA) [55]. Among 
the mitochondrial respiration parameters, CADD522-
mediated inhibition was mostly observed in the MRC, RC 
and AP (Figure 1B and 1C). The percent (%) inhibition 
of MRC and RC was more profound in MCF7-RUNX2 
cells than MCF7-Empty cells, which was also in a time-
dependent manner (Supplementary Figure 2B). Similar 
results were observed in cells treated with CADD522 for 
less than 30 hr (Supplementary Figure 2C and 2D). These 
results indicate that CADD522 significantly inhibits OCR 
in both ectopic RUNX2-expressing T47D and MCF7 cells 
as well as their Empty controls. Mean values of OCR and 
% inhibition of individual parameters are summarized in 
Supplementary Table 1.
To exclude the possibility that long-term use of 
G418 for selection and maintenance of stable cell lines 
might affect cellular OCR response to CADD522, we 
determined OCR in MDA-468 and MCF7 cells after 
exposure to CADD522 in the absence of G418. The OCR 
was determined in the absence of CADD522 at the time of 
analysis. CADD522 treatment for 6 hr in MDA-468 cells 
(Figure 2A) or MCF7 cells (Supplementary Figure 3A) 
did not have dramatic effects on the OCR compared to 
the vehicle control, whereas 24 hr of CADD522 treatment 
significantly suppressed the mitochondrial respiration 
parameters in MDA-468 cells (Figure 2A–2C). The 
percent (%) Inhibition of MRC and RC increased in a 
time-dependent manner (Figure 2B, right).
In addition, CADD522 significantly suppressed 
the baseline OCR (BL) of MDA-468 and MCF7 cells 
(Figure 2C). In MDA-468 cells, CADD522-mediated 
inhibition was greater after 24 hr than after 6 hr despite 
no difference between vehicle controls. Inhibition of 
the baseline OCR was clearly observed in both T47D-
Empty and -RUNX2 cells treated with CADD522 for 
72 hr, as well as in MCF7-Empty and -RUNX2 cells 
with CADD522 for 30 hr (Supplementary Figure 3B). 
However, no significant difference was observed in the 
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non-mitochondrial (antimycin A-resistant) OCR (NM, 
value at t = 63 min) between vehicle- and CADD522-
treated cells (Supplementary Figure 3C and Figure 1C), 
indicating that CADD522 targets mitochondria rather 
than other cellular sources of respiration. Taken together, 
our data clearly show that CADD522 represses the key 
mitochondrial respiration parameters. Our previous results 
showed that among thirteen BC cells lines tested, MDA-
468 and MCF7 cells displayed the highest sensitivity to 
CADD522 in short- and long-term cell growth assays even 
though MDA-468 and MCF7 cells express low levels of 
RUNX2 [52]. Therefore, CADD522 may target primarily 
mitochondria in BC cells with low levels of RUNX2.
Decrease in mitochondrial ATP production
When cells have limited glucose availability, ATP 
is synthesized mainly from mitochondria. Cells in culture 
medium with pyruvate or galactose but not glucose 
are primarily dependent on OXPHOS as glycolysis 
contribution to ATP generation is minimized. In contrast, 
under serum-free, glucose-supplemented conditions 
(Serum-Free Glucose M), normal mitochondrial function 
is compromised, and mitochondrial ATP production is 
suppressed. Indeed, we observed that BC cells in Pyruvate 
M or Galactose M exhibited lower levels of ATP than in 
Complete M owing to suppression of ATP production 
Figure 1: Inhibitory effect of CADD522 on mitochondrial OCR. (A) Acute OCR changes were determined in T47D-RUNX2 
and -Empty cells with no prior CADD522 treatment. Cells seeded in Seahorse plates were incubated overnight in growth medium without 
G418, and then replenished with Seahorse-Certified Medium on the assay day. Vehicle control (0.1% DMSO), Oligomycin or CADD522 
were directly injected into port A of the XF Extracellular Flux Analyzer, and OCR was measured. Data (% OCR) are presented as the 
percentage of the basal OCR value at t = 12 min (100%). Experiments were performed in four replicates and repeated twice (mean ± SD). 
O, Oligomycin (1 μg/ml); F, FCCP (1 µM, port B); P, pyruvate (10 mM, port C); AA, antimycin A (1 µM, port D). Red line, maximal OCR 
value of the Control at t = 57 min. (B) Cells were treated with CADD522 for 6~72 hr and replenished with Seahorse-Certified Medium 
with no CADD522. OCR was measured in the XF Extracellular Flux Analyzer. Data (mean ± SD) are presented as OCR (pMoles/min/µg 
protein). (C) Mitochondrial respiratory parameters were calculated as described in Material and Methods: Maximal respiratory capacity 
(MRC), mitochondrial reserve capacity (RC), ATP production-linked respiration (AP), proton leak-linked respiration (PL), baseline 
respiration (BL), and non-mitochondrial respiration (NM). Experiments were performed in four replicates and data are expressed as mean 
± SE from two independent experiments. *P < 0.05 compared to Empty cells with vehicle control (0.1% DMSO); #P < 0.05 compared to 
RUNX2-expressing cells with vehicle control.
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derived from glycolysis and possible changes in energy 
demand (Figure 3A, Supplementary Figure 4A).
To examine whether CADD522-induced OCR 
changes have a functional effect on ATP levels, we treated 
cells with CADD522 for a short period of time (4~6 hr) 
and determined changes in ATP levels by bioluminescence 
assay. CADD522 significantly inhibited ATP levels 
in BC cells, which was greater in cells incubated in 
media without glucose (Pyruvate M, Galactose M) than 
in complete M (Figure 3A). Consistently, ATP levels 
decreased in both ectopic RUNX2-expressing MCF7 and 
T47D cells and their Empty controls when glycolytic ATP 
generation was blocked (Figure 3B and 3C). However, 
CADD522 had little effect on ATP levels when cells were 
incubated in Serum-Free Glucose M (Supplementary 
Figure 4B), indicating that these cells are sensitive to 
CADD522-mediated ATP inhibition primarily under 
conditions when they depend on mitochondrial OXPHOS. 
Decreased ATP levels in response to CADD522 were 
observed when cells were treated with CADD522 for a 
relatively long period of time (24~48 hr) (Supplementary 
Figure 4C), and also were generally observed in BC cells 
regardless of their RUNX2 status.
Increased mitochondrial ROS generation
Mitochondria are a source as well as a target of ROS. 
Leakage of electrons from the ETC produces superoxide 
radicals. Mitochondrial respiration normally restricts 
ROS production since electron flow is very efficient, but 
suppression of respiration and ATP production result in a 
greatly enhanced rate of free radical production [15]. ROS 
consist of the oxygen radical superoxide anion (O2
•−) and 
hydroxyl radical (•OH) and non-radical oxygen species, 
such as hydrogen peroxide (H2O2) and singlet oxygen (O2). 
To determine whether inhibition of respiration (OCR) by 
CADD522 increases intracellular ROS levels, we treated 
cells with CADD522 for 6 or 24 hr and incubated cells with 
the fluorogenic dye CM-H2DCFDA that measures hydroxyl, 
peroxyl, and other ROS within cells [56]. CADD522 
significantly increased intracellular ROS production in 
both MCF7 and MDA-468 cells (Figure 4A). However, co-
treatment with N-acetyl-l-cysteine (NAC, 5 mM), a widely 
used antioxidant [57, 58], diminished the CADD522-
increased intracellular ROS levels to below the level of the 
control (Figure 4B). We further determined mitochondrial 
ROS levels in cells treated with CADD522 for 24 hr using 
MitoSox Red, a fluorescent dye relatively specific for 
superoxide. As shown in Figure 4C and 4D, CADD522 
increased the level of mitochondrial ROS in MCF7 and 
MDA-468 cells, which was more evident in serum-free 
than serum-containing condition. Similar results were 
observed in CADD522-treated ectopic RUNX2-expressing 
T47D and MCF7 cells as well as their Empty controls 
(Supplementary Figure 5A and 5B). In addition, CADD522-
regulated mitochondrial ROS levels were significantly 
Figure 2: Inhibition of mitochondrial OCR in CADD522-treated BC cells. (A) MDA-468 cells were treated with CADD522 
for 6 and 24 hr and replenished with Seahorse-Certified Medium with no CADD522. Data (mean ± SD) are presented as OCR (pMoles/
min/µg protein). O, Oligomycin (1 μg/ml); F, FCCP (1 µM, port B); P, pyruvate (10 mM, port C); AA, Antimycin A (1 µM, port D). (B) 
Mitochondrial respiration parameters in MDA-468 cells treated with CADD522 for 24 hr (left). Experiments were performed in four 
replicates and data are presented as mean ± SE from two independent experiments. *P < 0.05 compared to Control. Percent (%) inhibition 
of MRC and RC in MDA-468 cells treated with CADD522 (right). *P < 0.05 compared to % inhibition at 6 hr of treatment. (C) Baseline 
cellular OCR (BL) was calculated from basal respiration (value at t = 12 min) after subtracting NM. Experiments were done in four 
replicates and repeated twice (mean ± SE). *P < 0.05 compared to Control; #P < 0.05 compared to BL of CADD522-treated cells for 6 hr.
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reduced by mitochondria-targeted antioxidants MitoQ (5 
µM) [59] and MitoTEMPO (MitoT, 50 µM) [60] (Figure 
4E). These results indicate that part of ROS levels increased 
by CADD522 may be derived from mitochondria.
Inhibition of ATP synthase enzymatic activity
OCR is regulated by both ETC complex activity 
and the rate of ATP production from mitochondrial H+-
ATP synthase, a nuclear genome-encoded enzyme that 
is a central player in defining the bioenergetic activity 
of the cell. To investigate how CADD522 suppresses 
the level of ATP, we incubated BC cells in Complete 
M with CADD522 (50 µM) for 24 hr, and then isolated 
cell lysates to perform quantitative measurement of the 
mitochondrial ATP synthase activity. The ATP synthase 
enzyme was immunocaptured within the wells of a 
microplate and CADD522 was not further added during 
the assay. CADD522 significantly inhibited the activity 
of ATP synthase in BC cells (Figure 5A, left). Significant 
decrease of ATP synthase activity was also observed in 
ectopic RUNX2-expressing MCF7 cells treated with 
CADD522 for 24 hr (Figure 5B and 5C, Supplementary 
Figure 6A). Similar inhibition was observed even after a 
short treatment time in Galactose M (4 hr) (Figure 5A, 
right). These results indicate that reduced ATP synthase 
activity persists after CADD522 was removed during 
isolation of protein lysates.
To rule out that the inhibition could have been due to 
blocking upstream components of the ETC, protein lysates 
were prepared from MDA-231 and MDA-468 cells without 
prior CADD522 treatment. After immunocapture with 
specific antibody, the ATP synthase enzyme was incubated 
with CADD522 (0~2 µM) in vitro for 30 min. As seen 
in Figure 5D and Supplementary Figure 6C, CADD522 
decreased the slope of ATP synthase (i.e., inhibition of 
the activity) in either MDA-231 or MDA-468 cells in a 
concentration-dependent manner. These results suggest that 
lower ATP levels in response to CADD522 could be due to 
direct inhibition of the mitochondrial ATP synthase activity. 
The mean values of the ATP synthase activity of individual 
cells are shown in Supplementary Table 2.
No changes in MMP or mitochondrial Complex 
I activity
Under physiological conditions, mitochondrial 
membrane proton pumps of the ETC generate an 
Figure 3: CADD522 treatment suppresses the levels of ATP. (A) Cells were treated with CADD522 (50 µM) in Pyruvate M (4 
hr), Galactose M (4 hr) or Complete M (6 hr), and cellular ATP levels were determined. Galactose M, DMEM with 5 mM galactose, 1 mM 
pyruvate, no glucose, 2 mM glutamine, 10% serum; Pyruvate M, DMEM with 2 mM pyruvate, no Glucose, no Glutamine with 5% serum. 
Complete M, 25 mM glucose, 2 mM glutamine, 1 mM pyruvate, 10% serum. Experiments were done in four replicates and repeated twice 
(mean ± SD). *P < 0.05 compared to vehicle control (0.1% DMSO). Red line, ATP level of the control MDA-231 cells in Complete M. (B, 
C) Ectopic RUNX2 expressing cells and their Empty controls were treated with CADD522 in Pyruvate M (4 hr) or Galactose M (6 hr), and 
cellular ATP levels were determined. *P < 0.05 compared to the vehicle control of Empty cells; #P < 0.05 compared to the vehicle control 
of ectopic RUNX2-expressing cells.
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electrochemical proton gradient, the main component 
of which is MMP (∆Ψm). Proton pumping promotes 
normal respiratory function and synthesis of ATP to meet 
the energy needs of the cell. To determine the effect of 
CADD522 on MMP (∆Ψm), we incubated BC cells with a 
fluorescent ∆Ψm-sensitive dye, JC-1. However, we did not 
observe any significant difference of JC-1 fluorescence 
intensity between cells treated with vehicle and CADD522 
for 4~72 hr (Supplementary Figure 7A). Changes of JC-1 
fluorescence by CADD522 were also not observed in 
cells incubated with TMRM, another ∆Ψm-detecting dye. 
These results show that CADD522 targets mitochondria 
without causing significant collapse of ∆Ψm.
Complex I (NADH dehydrogenase) is the primary 
electron acceptor from the TCA cycle metabolite NADH. 
A blockade of the terminal OXPHOS step (mitochondrial 
ATP synthase) can also feedback to slow complex I 
activity, preventing efficient transfer of electrons, and thus 
leading to increased ROS [61]. We determined complex 
I activity under the same cell conditions described for 
measuring mitochondrial ATP synthase activity. However, 
complex I activity was not altered by CADD522 treatment 
Figure 4: CADD522 increases ROS level. (A, B) Cells were treated with CADD522 (50 µM) for 6 or 24 hr in complete growth 
medium, and intracellular ROS levels were determined with fluorescence-based CM-H2DCFDA. pH-adjusted NAC (5 mM, pH 7.2) was 
pre-treated for 1 hr and further incubated with CADD522 for 24 hr. Data (DCF fluorescence relative to Calcein green fluorescence) are 
presented as Fold, which was calculated from the relative value to the average of the vehicle control (0.1% DMSO, = 1). All determinations 
were in four replicates and repeated twice (mean ± SD). *P < 0.05 compared to the control; #P < 0.05 compared to CADD522 alone. (C) 
Cells were treated with CADD522 for 24 hr in complete growth medium, and mitochondrial superoxide levels were measured by incubating 
cells with MitoSox Red dye. (D) Cells were treated with CADD522 for 3 or 24 hr in serum-free medium (SFM), and mitochondrial 
superoxide levels were determined. (E) Mitochondria-specific antioxidants MitoQ (5 µM) and MitoTempo (MitoT, 50 µM) were pre-
treated for 1 hr and further incubated with CADD522 for 24 hr in serum-free condition.
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for up to 72 hr in all BC cells examined (Supplementary 
Figure 7B).
Interaction of α and β subunits of F1-ATP 
synthase with CADD522
Cellular thermal shift assay (CETSA) is used 
to assess drug: protein interactions based on the 
drug-induced thermal stabilization of target proteins 
(23828940, 29957028). Therefore, CETSA profiles a 
characteristic fingerprint of target engagement along the 
drug concentration axis [62, 63]. To delineate possible 
engagement of CADD522 with the F1-ATP synthase, we 
performed CETSA using specific antibodies to detect α- or 
β-F1-ATP synthase subunits (α-F1 & β-F1). The thermal 
melting profile of β-F1-ATP synthase in cell lysates with 
vehicle control (0.1% DMSO) revealed that at 58.2°C 
(= Tagg[75]) and 53.5°C (= Tagg[50]), 75% and 50%, 
respectively, of the β-F1-ATP synthase were aggregated 
and removed from solution (Figure 6A). To investigate 
drug concentration effects, we exposed cell lysates to 
high (0.14~100 µM) (Figure 6B) or low concentrations 
(0.00064~10 µM) of CADD522 (Supplementary Figure 
8A) at a fixed heating temperature of Tagg(75) (= 58.2°C). 
Band density of the β subunit increased as CADD522 
concentration increased, suggesting that CADD522 
stabilizes the protein upon heat challenge. Isothermal 
dose-response curves showed that 50% of the β-F1-ATP 
synthase remained stable with CADD522 at concentrations 
(EC50) of 1.60 µM (experiment 1) and 1. 94 µM 
(experiment 2). The Tagg(75) and Tagg(50) of the α-F1-
ATP synthase in lysates with vehicle control were similar 
to those of the β-F1-ATP synthase (57.5°C and 52.0°C, 
respectively) (Supplementary Figure 8B). CADD522 
Figure 5: CADD522 inhibits mitochondrial ATP synthase activity. (A) Cells were treated with CADD522 for 24 hr in Complete 
M or 4 hr in Galactose M, and ATP synthase activity (ATP Syn. Ac.) was determined in cell lysates (50 µl) using commercial kits according 
to the manufacturer’s instruction. Absorbance was measured every 2 min (kinetic program) at 340 nm. Fold-differences were calculated 
from the relative activity to the average of the vehicle control (0.1% DMSO, = 1). All determinations were in triplicate and repeated 
twice (mean ± SD). *P < 0.05 compared to Control. (B) MCF7-RUNX2 and MCF7-Empty cells were treated with CADD522 for 24 hr in 
Complete M, and mitochondrial ATP synthase activity was determined. *P < 0.05 compared to MCF7-Empty cells with vehicle treatment. 
Experiments were performed in triplicate and repeated twice (mean ± SD). #P < 0.05 compared to MCF7-RUNX2 with vehicle treatment. 
(C) A representative result of mitochondrial ATP synthase activity showing changes of Ratio over time. Ratio, relative absorbance to the 
absorbance at 0 min. (D) Cell lysates (50 µg) isolated from MDA-231 and MDA-468 cells that were not treated with CADD522 were 
directly incubated with CADD522 for 30 min, and the in vitro ATP synthase activity was determined. 0.05% DMSO was used as vehicle 
control. Relative activity is expressed as changes in absorbance or Ratio per minute (∆Absorbance or ∆Ratio)/∆min.
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increased stability of the α-F1-ATP synthase upon heat 
challenge (Supplementary Figure 8C). The EC50 of 
CADD522 for the α-F1-ATP synthase was lower than 1 
µM (< 0.14 µM). These results indicate that CADD522 
may interact with both α- and β-F1-ATP synthase. To 
confirm binding of CADD522 with F1-ATP synthase, 
we performed differential scanning fluorimetry (DSF), 
which monitors thermally-induced protein denaturation 
[64]. For this, we used purified, recombinant α- or β-F1-
ATP synthase instead of crude lysates. Results showed 
that CADD522 (25~200 µM) increased significantly 
the melting temperature (Tm) of the purified α-F1-ATP 
synthase (Supplementary Figure 8D, left), indicating that 
CADD522 increased stability of the α subunit from heat 
denaturation. However, no significant change in the Tm of 
the recombinant β subunit was observed (Supplementary 
Figure 8D, right).
CADD522 further enhances ROS levels under 
conditions of oxidative stress
ROS such as superoxide are converted to H2O2 
within cells by superoxide dismutases [65, 66], and thus, 
a change in H2O2 can reflect a general change in the ROS 
level. Before evaluation of the effect of CADD522 on H2O2 
levels, we first added CADD522 into Complete M without 
cells and incubated for 6 hr to verify that CADD522 
itself does not generate ROS in culture medium. We 
determined the level of ROS using a commercial kit that 
generates luminescent signals (Luc) proportional to H2O2 
concentrations. As shown in Supplementary Figure 9A 
(left), CADD522 did not significantly change H2O2 Luc 
compared to the vehicle control.
Cells treated with CADD522 for 6 hr also did not 
show a significant difference in the intensity of H2O2 Luc 
compared to the vehicle control (Supplementary Figure 
9A, middle), which was inconsistent with intracellular 
ROS levels determined by CM-H2DCFDA (Figure 4A). 
This may be because of differences in assay sensitivity. 
However, CADD522 treatment for 18 hr significantly 
increased the intensity of H2O2 Luc in MDA-231 and 
MDA-468 cells, although the intensity was still low (< 
100) (Supplementary Figure 9A, right).
Exogenous H2O2 (25 µM) generated a high level of 
H2O2 Luc intensity in cell culture medium without cells, 
and the intensity decreased in the presence of MDA-231 
cells (Supplementary Figure 9B), which may be due to ROS 
quenching by cellular antioxidants or catalase. However, 
co-treatment with CADD522 and H2O2 for 6 hr further 
increased the H2O2 Luc intensity in MDA-231 cells. Similar 
results were observed in other BC cells co-treated with 
CADD522 and H2O2 for 6 hr (Supplementary Figure 9C) 
Figure 6: Engagement of CADD522 with the mitochondrial F1-ATP synthase, β subunit. (A) Left: representative immunoblot 
result of the β-F1-ATP synthase upon heat challenges. Multiple aliquots of cell lysate isolated from MDA-231 cells were heated in the 
absence of CADD522 in temperature-gradient thermocycler (38~60°C) for 10 min. After cooling, the samples were centrifuged to separate 
soluble fractions from precipitated proteins. Western blotting was performed for the β subunit using a specific antibody. DMSO, vehicle 
control (0.1%); β-F1, β-F1-ATP synthase. Right: thermal melting profile of the β-F1-ATP synthase. Band density of the the β subunit was 
quantified, normalized to loading (37°C), and analyzed for CETSA melting curves. Experiments were performed in three replicates (mean ± 
SD) and repeated twice. (B) Left: representative immunoblot result of the β-F1-ATP synthase upon increasing concentrations of CADD522. 
Right: dose-response target engagement of CADD522 in the β-F1-ATP synthase was performed at 58.2°C. Density of the the β subunit was 
quantified, normalized to the vehicle control (0.1% DMSO), and analyzed for melting curves.
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and 24 hr (Figure 7A), and BC cells pre-treated with 
CADD522 for 18 hr and then co-treated with H2O2 for 
an additional 6 hr (Figure 7B). Notably, the H2O2 Luc 
intensity increased as the concentration of exogenous H2O2 
increased, which was further increased in the presence of 
CADD522 (Figure 7A).
tert-Butyl hydroperoxide (t-BHP) is an organic 
peroxide that induces oxidative damage and cell death 
[67]. To circumvent ROS scavenging by serum, we 
treated MCF7 and MDA-468 cells with CADD522 
and/or t-BHP in serum-free medium (SFM) for 4 hr. 
Intracellular ROS levels were increased significantly by 
t-BHP alone (Figure 7C, Supplementary Figure 10A), 
and considerably enhanced by combined CADD522 and 
t-BHP treatment (Figure 7C). NAC (5 mM) robustly 
reduced the augmented ROS levels in both cell lines. A 
single treatment of CADD522 or t-BHP in SFM for 4 
hr did not induce acute cell death in MCF7 and MDA-
468 cells (cell viability ≥ 70%), whereas the combined 
treatment significantly decreased the viability (≤ 40%) 
(Supplementary Figure 10B). NAC completely blocked 
the combined treatment-induced cell death. Similar results 
were observed in MCF7 or MDA-468 cells co-treated in 
SFM for 24 hr, and in MDA-231 cells in Gal M (4 hr or 24 
hr) (Supplementary Figure 10C).
Furthermore, when MDA-231 cells were grown in 
Complete M for 24 hr, CADD522 had little effect on the 
t-BHP-mediated cell growth inhibition (Supplementary 
Figure 10D, middle). However, pre-treatment with 
CADD522 for 24 hr before co-treatment significantly 
increased the t-BHP-mediated cell growth inhibition 
(Figure 7D), which was similar to that in cells treated 
simultaneously for 72 hr (Supplementary Figure 10D, 
right). Specifically, when MDA-231 cells were treated 
concomitantly for 72 hr, the cell growth at 10 µM t-BHP 
was 72.34 ± 4.25% in the vehicle control and 47.26 ± 
6.28% in CADD522-treated cells. When cells were pre-
treated with CADD522 for 24 hr and consecutively co-
treated with t-BHP for additional 24 hr, the cell growth at 
10 µM t-BHP was 74.43 ± 9.02% in vehicle control and 
47.18 ± 4.41% in CADD522 treatment.
Menadione (Vitamin K3, a precursor of Vitamin 
K) is known to act as an anticancer agent in BC via 
the mitochondria-mediated apoptotic pathway [68, 
69]. Menadione induces ROS and rapidly lowers ATP 
in MCF7 cells [68] and MDA-231 cells [70] through 
intracellular redox cycling [70]. The IC50 (50% inhibitory 
concentration) of Menadione in MCF7 and MDA-231 
cells was reported to be 15 µM and 9 µM, respectively 
[68, 70]. To evaluate if Menadione potentiates the 
antiproliferative effects of CADD522 on BC cells, we 
treated MCF7 and MDA-231 cells with Menadione 
at a sublethal concentration (5 µM) in the presence or 
absence of CADD522 (0~100 µM) for 72 hr. CADD522 
Figure 7: Enhanced ROS levels in the presence of ROS generating agents. (A) Cells in Complete M were treated with 
CADD522 (50 µM) in the presence of increasing concentration of H2O2 (0~100 µM) for 24 hr. The H2O2 Luc intensity was determined 
as described in Materials and Methods. Note, The H2O2 Luc intensity indicates Values at Y-axis × 1,000. Experiments were performed 
in triplicate and repeated twice (mean ± SD). *P < 0.05 compared to Control with no H2O2 treatment; 
#P < 0.05 compared to Control at 
indicated H2O2 concentrations. (B) B cells were treated with CADD522 for 18 hr, and then coincubated with H2O2 for additional 6 hr. 
*P 
< 0.05 compared to Control. (C) Intracellular ROS levels were determined in MCF7 and MDA-468 cells after cells were treated with 
CADD522 and/or t-BHP for 4 hr in SFM. NAC (5 mM) was pretreated for 1 hr and further treated with CADD522 and t-BHP. Data are 
presented as the relative value to Control (Fold). Experiments were done in four replicates and repeated twice (mean ± SD). *P < 0.05 
compared to Control; **P < 0.001 compared to t-BHP alone; #P < 0.001 compared to CADD522 + t-BHP. (D) MDA-231 or MDA-468 
cells were pretreated with CADD522 for 24 hr and further treated with t-BHP for 24 hr in the presence of CADD522. Cell growth was 
determined by crystal violet staining. *P < 0.05 compared to no treatment; #P < 0.05 compared to Control at indicated t-BHP concentrations.
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alone exerted higher growth inhibition in MCF7 cells 
than MDA-231 cells as reported [52], but MDA- 231 
cells showed greater sensitivity to Menadione (57.82 ± 
3.34%) than MCF7 cells (78.22 ± 3.50%) (Supplementary 
Figure 10E). In the presence of CADD522, the sensitivity 
of MDA-231 and MCF7 cells to Menadione increased 
significantly, which was more discernible in MDA-231 
cells than in MCF-7 cells. The growth of MDA-231 cells 
was 31.61 ± 0.90% and that of MCF7 cells was 47.45 ± 
3.79% in the presence of 50 µM CADD522. These data 
support the conclusion that CADD522, through its ability 
to elevate cellular ROS, is more effective at inhibiting 
proliferation when additional ROS-generating systems 
are provided.
NAC attenuates the inhibitory effect of 
CADD522 on BC cells growth
Pre-treatment of tumor cells with NAC, a general 
ROS scavenger has been shown to provide protection 
against the cytotoxicity of intracellular oxidants [58, 71]. It 
is known that NAC can inhibit apoptosis [57] induced by 
ROS. To address the role of ROS in CADD522-mediated 
cell growth inhibition, we pre-treated BC cells with the 
antioxidant NAC (5 mM, pH adjusted to neutrality) for 
1 hr and then co-treated with CADD522 (0~500 µM) for 
72 hr. NAC moderately but significantly attenuated the 
CADD522-mediated cell growth inhibition (Figure 8A), 
indicating that the inhibition is partially ROS-dependent. 
In addition, NAC attenuated the CADD522-inhibited 
tumorsphere formation of BC cells (Figure 8B). The 
number of tumorspheres in cells treated with NAC in the 
presence of CADD522 (NAC+CADD522) was similar to 
that of the vehicle control, and importantly, the size and 
shape of the tumorspheres in cells with NAC+CADD522 
were not disrupted compared to the vehicle controls 
without NAC (Supplementary Figure 11A). These results 
indicate that CADD522 may exert its antitumor activity 
at least through increased ROS levels and oxidative cell 
damage.
Effect of CADD522 and RUNX2 KD on 
expression of mitochondria-associated genes
To begin to explore the molecular mechanisms 
that underlie how CADD522 or RUNX2 KD regulates 
mitochondrial function, we first determined mRNA levels 
of mitochondrial ETC and ATP synthase-encoding genes 
by quantitative PCR analysis. Results show that, overall, 
mRNA levels of these genes were not considerably 
different between RUNX2 KD and NTC of Hs578t cells 
or between CADD522-treated BC cells and the vehicle 
control (Supplementary Figure 12A–12D). One exception 
was the mRNA level of ATP5B (mitochondrial ATP 
synthase F1 subunit beta, β-F1-ATP synthase), which 
was markedly decreased by CADD522 in MDA-468 
and MCF7 cells. RUNX2 KD significantly increased the 
level of PGC-1α, the master regulator of mitochondrial 
biogenesis, but had no effects on the levels of nuclear 
genes that regulate mitochondrial DNA transcription 
and replication (Supplementary Figure 12E). On the 
contrary, CADD522 significantly inhibited mRNA levels 
of the majority of mitochondrial biogenesis-related genes 
examined (Supplementary Figure 12F). Notably, the 
expression level of PGC-1α mRNA in MCF7 cells was 
almost completely suppressed by CADD522.
DISCUSSION
Some BC cells expressing RUNX2 exhibit altered 
metabolic requirements, with reduced mitochondrial 
respiration and increased glycolysis [52, 54]. Under 
conditions where cellular ATP production is dependent 
on mitochondrial OXPHOS (Pyruvate M or Galactose 
M), ATP levels were lower in T47D-RUNX2 and MCF7-
RUNX2 cells compared to their Empty controls (Figure 
3B and 3C). However, in Serum-Free Glucose M in which 
mitochondrial ATP production was suppressed, ATP levels 
increased slightly but significantly in ectopic RUNX2-
expressing cells (Supplementary Figure 4B, left), which 
may be due to RUNX2-mediated increases in glycolysis 
that result in increased ATP synthesis [52]. In complete 
M, ATP levels did not change (Supplementary Figure 
4B, right). The ATP synthase activity also decreased in 
ectopic RUNX2-expressing cells compared to their Empty 
controls (Figure 5B and 5C, Supplementary Figure 6A and 
6B, Supplementary Table 2).
Our results identify CADD522 as a novel OXPHOS 
inhibitor. The maximal respiratory capacity (MRC) and the 
reserve capacity (RC) between ectopic RUNX2-expressing 
cells and their Empty controls were not different 
(Supplementary Figure 2E), but CADD522-mediated 
inhibition of MRC and RC was higher in MCF7-RUNX2 
cells than -Empty cells. These results suggest that RUNX2 
might render BC cells more sensitive to CADD522. In 
addition, inhibition of OCR with CADD522 treatment 
was observed in MCF7 and T47D cells expressing either 
ectopic RUNX2 protein or low levels of baseline RUNX2. 
Decreased ATP levels were also observed in several BC 
cell lines regardless of their RUNX2 status. Moreover, 
intracellular and mitochondrial ROS levels increased in 
CADD522-treated ectopic RUNX2-expressing T47D and 
MCF7 cells (Supplementary Figure 5A and 5B) as well 
as Hs578t cells with RUNX2 KD. These findings suggest 
that the inhibitory effects of CADD522 on mitochondria 
are RUNX2-independent.
Recent findings indicate that glycolysis and 
mitochondrial OXPHOS cooperate under hypoxic and 
nutrient-deprived selective pressures for cancer cell 
growth. Under poorly perfused conditions, stem-like 
cancer cells that rely on mitochondrial OXPHOS for their 
survival exhibit drug resistance and increased metastatic 
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potential [72]. Tumors that exist in nutrient-poor 
environments are not highly proliferative but continue 
to survive [73, 74] and, consequently, drugs that block 
mitochondrial ATP production are predicted to induce 
cell death in poorly perfused tumors. Tumors that show 
a heavy dependence on OXPHOS for ATP production 
(i.e., cancer stem cells) appear to be more sensitive to 
drugs that limit mitochondrial ATP production since these 
tumors do not compensate for reduced mitochondrial 
ATP by increasing glycolytic ATP [42, 75–77]. Our 
published data suggests that blockage of RUNX2 with 
CADD522 inhibits glycolytic gene expression and 
reduces glucose uptake [52]. Our current results show 
that CADD522 decreased ATP production in cells under 
conditions of limited glucose availability. Therefore, a 
dual mechanistic basis for CADD522 action in BC may 
be operative: RUNX2-mediated glycolysis inhibition 
through suppression of Glut-1 gene expression [52] and 
RUNX2-independent mitochondrial dysfunction through 
repression of the activity of mitochondrial ATP synthase, 
an alternative target for CADD522. Our data showing 
that CADD522 and RUNX2 KD additively enhanced 
inhibition of cell growth and colony forming ability of BC 
cells (Supplementary Figure 11B and 11C) are supportive 
evidence for this concept. Moreover, CADD522 can 
synergize with therapies that diminish glycolysis 
[20, 78]. Indeed, we observed that concurrent treatment 
of CADD522 with 2-deoxyglucose (2-DG, an inhibitor of 
glucose uptake) significantly increased the sensitivity of 
MDA-231 cells to CADD522 (Supplementary Table 3). 
Therefore, CADD522 demonstrates mechanistic proof of 
concept by targeting mitochondrial ATP production alone 
and in combination with glycolysis inhibitors.
Oligomycin inhibits ATP synthase activity because it 
blocks proton (H+) translocation across the mitochondrial 
inner membrane (Fo subunits). Rotation of the central 
stalk against the surrounding α(3)β(3) subunits leads to 
synthesis of ATP at three separate catalytic domains on 
the β subunits [79, 80]. Our results are evidence that 
CADD522 inhibits the ATP synthase activity in both cell 
culture and cell-free lysates. The enzymatic assay used 
in our study measures the F1-mediated ATP hydrolysis 
activity (ATPase) as a surrogate for ATP synthase activity. 
In this in vitro system, the FoF1-ATP synthase/ATPase 
cannot use the mitochondrial protonmotive force (∆p) 
for ATP synthesis as there is no membrane gradient after 
immunocapture. The FoF1-ATP synthase thus does not 
exhibit Fo-dependent, proton-coupled enzymatic activity. 
Therefore, the F1 components of the ATP synthase are 
likely potential CADD522 targets.
Indeed, we identified the α and β subunits of the 
F1-ATP synthase as potential CADD522 interacting 
proteins, supporting that both α and β subunits of the 
F1-ATP synthase may be the actual CADD522 targets. 
In both CETSA and DSF, which use total protein lysates 
and purified individual proteins, respectively, CADD522 
increased the protein stability of the α-F1-ATP synthase 
against heat challenge. CADD522 increased the stability 
Figure 8: NAC protects BC cells from CADD522-mediated growth inhibition. (A) Cells were pre-treated with NAC (5 mM, 
pH adjusted to 7.2) for 1 hr, and cotreated with CADD522 (50 µM) for 72 hr. Cell growth was determined by crystal violet staining. 
Data are presented as mean ± SD. Experiments were done in triplicate and repeated twice. *P < 0.05 compared to cells without NAC at 
indicated CADD522 concentrations. Red line, 50% of cell growth. (B) Cells were plated in low attachment plates and cotreated with NAC 
and CADD522 at the initial day of cell plating. Cells were incubated in suspension for 7 days. Data presented as mean ± SD. Experiments 
were done in triplicate and repeated three times. *P < 0.05 compared to Control; #P < 0.05 compared to cells treated with CADD522 in the 
absence of NAC.
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of the β-F1-ATP synthases in total lysates, whereas it 
could not protect the purified, recombinant β-F1-ATP 
synthases from heat denaturation. These results suggest 
that CADD522 may directly interact with the α subunit, 
but indirectly with β subunit. Many F1-ATP synthase 
complex inhibitors interact with α and/or β subunits, 
but most common interaction sites for these inhibitors 
are known to be at the three α/β interface sites of the 
F1 complex [43]. With recombinant F1-ATP synthase 
components, we will validate in future studies whether 
individual α and β subunits or the α/β interaction sites 
are the relevant target, and how changes in α and/
or β stability could account for CADD522 effects 
on mitochondrial ATP synthase activity [43]. Highly 
specific, cutting edge drug-protein interaction assays 
such as in vivo surface plasmon resonance (SPR) [81, 82] 
will be helpful to uncover at which sites of the F1-ATP 
synthase complex the functional binding occurs.
We reported that CADD522 promotes growth arrest 
rather than apoptosis [52]. Apoptosis can be activated with 
the use of compounds targeting key protein components 
of the mitochondria such as Bcl-2 family proteins (pro-
survival Bcl-2 and Bcl-xL and pro-apoptotic Bax and 
Bak) [83]. The activity of OXPHOS is required for the 
function of the proapoptotic protein Bax in yeast and 
mammalian cells [42, 76, 84], which is dependent upon 
the mitochondrial FoF1-ATP synthase proton pump [77]. 
Oligomycin A, an inhibitor of Fo-portion of the H+-ATP 
synthase, halts the efficient execution of apoptosis [84, 85] 
and suppresses TNF-induced apoptosis [86]. This suggests 
that the activity of mitochondrial OXPHOS may be also 
required for the overall apoptotic potential of BC cells 
[86–89]. Therefore, the inhibitory effect of CADD522 on 
the activity of the FoF1-ATP synthase could be one of the 
reasons that CADD522 does not induce apoptotic changes 
in BC cells [52].
Metformin lowers ATP production through inhibition 
of mitochondrial ETC complex I [90]. Unlike metformin, 
CADD522 diminished ATP levels through inhibition of 
mitochondrial ATP synthase activity, without alteration 
of complex I activity. Oligomycin inhibits mitochondrial 
ATP synthase, which leads to changes in MMP (∆Ψm) 
[79, 80]. However, CADD522 had no effect on changes 
in the ratio of red to green fluorescence intensity of JC-
1, indicating little changes in the overall MMP (∆Ψm). 
Targeting glycolysis and OXPHOS may lead to tissue 
toxicity. However, our previous report demonstrated the 
translational potential of CADD522 in in vitro and in 
vivo tumor models without exhibiting in vitro and in vivo 
toxicity [52]. Consistently, we did not observe significant 
difference in cell viability between CADD522- and vehicle-
treated groups even when OCR and mitochondrial ATP 
synthase activity were substantially inhibited. Therefore, 
CADD522 may be uniquely different from other ATP 
synthase inhibitors (such as oligomycin) that demonstrate 
cytotoxicity and thus have no clinical application.
ROS production increases intracellular signaling and 
tumorigenesis but also is deleterious to cells, depending 
on the level and temporal expression of ROS, which may 
be cell-type specific [91–93]. Similarly, antioxidants 
have been shown to exhibit either pro-tumorigenic 
or anti-tumorigenic activity [92, 94, 95]. Many drugs 
target mitochondrial ATP synthase activity to lower ATP 
levels and increase ROS within mitochondria [15, 22]. 
Benzodiazepine (Bz-423) [96] and oligomycin A [97, 98] 
generate ROS from the respiratory chain by inhibition of 
mitochondrial ATP synthase. Therefore, the suppressed 
ATP synthase activity could contribute to the CADD522-
mediated increase of ROS formation in mitochondria. 
CADD522 itself does not generate ROS but elevates ROS 
in cell-based systems. A combination of CADD522 with 
pro-oxidants that simultaneously increase ROS production 
might be more useful to limit cancer cell growth. For 
example, the combination of CADD522 with t-BHP 
or menadione further enhanced ROS levels and growth 
inhibition of MDA-231 cells. Our finding that N-acetyl 
cysteine (NAC) attenuates the CADD522-inhibited 
tumorsphere formation and cell proliferation in BC cells 
indicate that ROS might be responsible for CADD522-
induced cell growth inhibition. Therefore, an increase in 
ROS could provide a therapeutic advantage if CADD522 
also inhibits glycolysis through RUNX2 inhibition [52].
Oxygen consumption rate (OCR) is a feature 
of oxidative phosphorylation while the extracellular 
acidification rate (ECAR) usually depends on glycolysis. 
However, we did not observe a significant CADD522-
induced change in ECAR (mpH/min/µg protein) in any 
cell lines tested. This may be due to buffering by HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
that we freshly added to Seahorse-certified medium 
just before the assays. Addition of HEPES is known to 
provide a buffering capacity to cell culture medium to 
maintain physiological pH (7.2~7.6) despite changes in 
CO2 concentration produced by respiration. When cells 
are outside of a CO2 incubator to be processed on the 
XF Extracellular Flux Analyzer, HEPES can work as a 
“Good” buffer [99], thus maintaining neutral pH even 
under conditions that increase ECAR with inhibition of 
mitochondrial respiration.
The mitochondrial metabolic properties of cancer 
cells are different from those of normal cells. In contrast 
to normal cells, actively growing tumor cells exhibit 
increased mitochondrial biogenesis and respiration for ATP 
generation to meet energy demands and maintain survival 
[100, 101]. Cancer stem cells are slow-growing cells that 
harbor tumorigenic potential, self-renewal capabilities, and 
intrinsic resistance to conventional and targeted therapies. 
These cells are dependent on active mitochondria and 
show increased oxygen consumption and ATP production 
compared to more highly proliferating tumor cells [100, 
102–104]. Therefore, inhibition of the mitochondrial 
respiratory chain can be exploited to develop selective 
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anticancer agents [26], since drugs targeting the ETC 
can preferentially kill cancer cells [22]. We reported that 
cell growth inhibition by CADD522 was significant in 
13 different BC cells (TNBC, ER+, and HER2+), while 
resistance of normal epithelial cells to CADD522 was 
commonly observed [52]. Moreover, tumorspheres 
organized from stem-like BC cells in suspension culture 
(MCF7, MDA-231, MDA-468) were sensitive to 
CADD522 treatment, but MCF10A cells that resemble 
normal mammary epithelial cells (mammospheres) were 
resistant [52]. Therefore, the higher sensitivity of BC cells 
to CADD522 compared with normal epithelial cells might 
be due to inhibitory effects of CADD522 on mitochondrial 
OXPHOS and the increased ROS levels.
Mitochondrial biogenesis is the process via which 
cells increase their individual mitochondrial mass [105]. 
RUNX2 KD in Hs578t cells increased the mitochondrial 
mass, which was reflected by increased fluorescence 
intensity of MitoTracker Green dye, and the mRNA level 
of PGC-1α, indicating that RUNX2 might be involved 
in regulation of mitochondrial biogenesis. CADD522 
treatment for 12 hr did not change mRNA levels of 
mitochondria-encoded genes (CytoB, MT-ATP6, MT-
CO2, etc.). However, CADD522 significantly decreased 
the mRNA levels of nucleus-encoded mitochondrial 
genes (PGC-1α, NRF-1, TFB2M, etc.) that activate the 
expression of key metabolic genes regulating respiration 
and mitochondrial DNA transcription and replication. 
Therefore, we do not exclude the possibility that 
CADD522 might interfere with mitochondrial dynamics 
through regulation of nuclear genes whose products 
target the processes that regulate mitochondrial content, 
structure, and function. Further studies will be needed to 
verify the precise effects of CADD522 on regulation of 
mitochondrial biogenesis.
Moreover, expression of the catalytic subunit β-F1-
ATP synthase is tightly regulated by post-transcriptional 
mechanisms that affect mRNA localization, stability and 
translation [106–110]. The mRNA expression of ATP5B in 
MCF7 and MDA-468 cells was substantially decreased by 
CADD522 treatment. These results indicate that CADD522 
might inhibit ATP synthase activity through regulation of 
target gene expression levels and/or the activity of the 
catalytic β subunit of the mitochondrial F1-ATP synthase. In 
summary, our findings demonstrate that mitochondrial ATP 
synthase inhibition may be a valid therapeutic approach and 
that one mechanism that drives sensitivity of BC cells to 
CADD522 is suppression of mitochondrial metabolism.
MATERIALS AND METHODS
Cell lines and reagents
All BC cell lines were obtained from American Type 
Culture Collection. Cells were subjected to routine cell 
line quality examinations (e.g., morphology, Mycoplasma) 
every 6 months. The cells for experiments were passaged 
for less than 6 months. Cell lines were maintained in 
DMEM/F12 (50:50) (BT474 and MDA-MB-468), 
RPMI1640 (HCC1937, HCC1428, BT549, HCC70), 
McCoy-5A (SKBr3), and DMEM (all other BC cancer 
cells) supplemented with 10% FBS, 100 U/mL penicillin 
and 100 mg/mL streptomycin. Establishment of T47D and 
MCF7 cells stably expressing ectopic RUNX2 (T47D-
RUNX2 and MCF7-RUNX2), and their empty vector 
controls (T47D-Empty and MCF7-Empty) were previously 
described [52]. These cells were maintained under G418 
(0.5~1 mg/ml). Hs578t cells with RUNX2 knockdown (KD) 
(55.5), a negative clone of RUNX2 KD cells (54.5) and non-
targeting control cells (NTC) were previously described [52, 
54]. These cells were maintained under puromycin (1 μg/
ml). Notably for experiments, to avoid unwanted effects of 
G418 or puromycin on mitochondria, these cells were plated 
in cell culture medium without antibiotics and incubated 
for a day, and then processed immediately or treated with 
CADD522 in antibiotics-free medium. CADD522 was 
purchased from ChemBridge Corporation (San Diego, CA). 
Other drugs or agents were purchased from Sigma-Aldrich 
(St Louis, MO, USA). Small-Interfering RNA (siRNA) pool 
targeting RUNX2 and non-targeting control were purchased 
from Dharmacon (Lafayette, CO, USA), and transfected into 
cells using RNAiMAX Reagent (Invitrogen).
Mitochondrial oxygen consumption rate (OCR)
Dynamic changes in OCR, a result of oxidative 
phosphorylation, were measured in live cells using the 
Seahorse XF24 Extracellular Flux Analyzer (Agilent 
Technologies, Santa Clara, CA, USA) according to 
the manufacturer’s instructions. BC cells were seeded 
(> 60,000 cells/well) in 24-well Seahorse plates and 
incubated in complete growth medium. The following 
day, cells were treated with CADD522, and incubated 
up to 72 hr. At the time of OCR measurement, cells were 
replenished with fresh Seahorse-XF DMEM (Cat. No. 
102365-100) supplemented with 5 mM HEPES, 5 mM 
glucose and 1% serum (pH-adjusted to 7.4 with Tris base 
powder) in the absence of CADD522 and incubated for 
one hour at 37°C in a non-CO2 incubator for stabilization 
of temperature and pH. Cell plates were then loaded 
onto the Seahorse Analyzer equipped for the sequential 
addition of final concentrations of oligomycin (1 µg/ml), 
carbonylcyanide-4-trifluoromethoxyphenylhydrazone 
(FCCP, 1 µM), Pyruvate (10 mM) and Antimycin A (1 
µM), with compounds that were freshly prepared just 
before use. In some experiments, we added FCCP and/or 
Pyruvate to two or three ports in the flux analyzer without 
oligomycin to maximize and prolong the respiratory 
reserve capacity measurement. At the end of the assay, 
total protein content in individual wells was determined 
and used for normalization of raw OCR values. OCR was 
expressed as pMoles/min/µg protein.
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To determine the acute OCR response in separate 
experiments, T47D-RUNX2 and -Empty cells without 
prior CADD522 treatment were replenished with Seahorse 
medium an hour before the assay. At the time of the 
assay, the assay buffer with 0.1% DMSO, oligomycin or 
increasing concentrations of CADD522 (10~200 µM, final 
concentration) was injected into port A, and the OCR was 
measured at 37°C. Data are presented as OCR (%), the 
percentage of the basal OCR at t = 12 min.
Mitochondrial respiration (OCR) was calculated 
as maximal respiratory capacity (MRC) by subtracting 
non-mitochondrial respiration (NM, OCR value at t = 
63 min) from the FCCP rate; ATP production-linked 
respiration (AP) by subtracting the oligomycin rate from 
baseline cellular OCR; proton leak-linked respiration 
(PL) by subtracting NM from the oligomycin rate; and 
mitochondrial reserve capacity (RC) by subtracting 
basal respiration (OCR value at t = 12 min) from MRC 
(Supplementary Figure 2, right). Baseline cellular OCR 
(BL) was calculated from basal respiration after subtracting 
NM [111]. Percent (%) inhibition of the individual 
parameters was calculated from the equation (A−B)/A × 
100; A, vehicle control; B, CADD522 treatment.
ATP assay
Cells were treated with CADD522 for the indicated 
time periods in pyruvate medium (Pyruvate M, 2 mM 
pyruvate, no glucose, no glutamine, 5% serum), galactose 
medium (Galactose M, 5 mM galactose, 1 mM pyruvate, 
no glucose, 2 mM glutamine, 10% serum), normal cell 
growth medium (Complete M, 25 mM glucose, 2 mM 
glutamine, 1 mM pyruvate, 10% serum), or Serum-Free 
Glucose M (25 mM glucose, no glutamine, no pyruvate, 
0% serum), and ATP level was determined using 
Luminescent ATP Detection Assay Kit purchased from 
Abcam (Boston, MA) as per manufacturer’s instructions. 
After addition of the assay mixture containing luciferin 
and luciferase, luminescence was measured using a 
Wallace microplate luminescence reader (Perkin Elmer, 
Waltham, MA, USA).
Intracellular reactive oxygen species (ROS) and 
mitochondrial superoxide levels
Cells in 96 well plates were treated with CADD522 
in normal growth or serum-free medium (SFM). To detect 
the intracellular formation of ROS, cells were incubated 
with a fluorogenic dye 2′,7′-dichlorofluorescein diacetate 
(CM-H2DCFDA, 25 µM) (ThermoFisher Scientific) for 
1 hr. This dye produces the highly fluorescent product 
2′,7′-dichlorofluorescein (DCF) upon reaction with ROS. 
The fluorescence was measured at 488/535 nm (Ex/Em) 
using a SYNERGY/HTX multimode reader (BioTek). 
CM-H2DCFDA is more sensitive to oxidation by 
hydrogen peroxide (H2O2) than superoxide [112].
To detect mitochondrial superoxide levels, cells 
were incubated with MitoSox Red (5 µM) (ThermoFisher 
Scientific) in HBSS for 10 min and the fluorescence 
was measured at 510/580 nm (Ex/Em). In parallel, the 
cell viability of cells receiving the same treatments was 
determined using the cell-permeant dye Calcein-AM (2 
µg/ml) (ThermoFisher Scientific). The nonfluorescent 
Calcein-AM is converted to green-fluorescent Calcein by 
intracellular esterases in live cells, which is measured at 
495/515 nm (Ex/Em). DCF or MitoSox Red fluorescence 
was divided by Calcein green fluorescence to normalize 
the ROS signal for cell viability.
Mitochondrial ATP synthase activity assay
Quantitative measurement of the activity of 
mitochondrial ATP Synthase was performed using the 
ATP Synthase Enzyme Activity Microplate Assay Kit 
that is commercially available (Abcam, ab109714). After 
cells were treated with CADD522 for the indicated period 
of time in Complete M, cells were harvested and cell 
lysates were extracted in buffers provided by the kit. ATP 
synthase is localized in the mitochondria and the plasma 
membrane of highly proliferating cells in eukaryotes [32, 
50]. Therefore, homogenized samples (cell lysates) were 
frozen, thawed and pelleted by centrifugation at ~16,000 
rpm to fracture the plasma membranes and remove soluble 
non-membrane associated proteins as per manufacturer’s 
instruction. Pelleted samples were resuspended in the 
supplied buffer. Enzymes in cell lysates (50 µl/well) 
were immunocaptured within the wells of the microplate 
and enzyme activity was determined by following the 
reduction of substrates, coupled to the reduction of a 
reporter dye to yield a colored reaction. Absorbance of 
each well was measured every 2 min for up to 90 min in 
a spectrophotometer purchased from BioTek Instruments 
(SYNERGY/HTX multimode reader) (Winooski, VT, 
USA) at a wavelength of 340 nm (kinetic program), and 
the slope (= − Enzyme Activity) was calculated from the 
linear range in each curve by the equation ([ΔAbsorbance 
or ΔRatio]/Δmin/μg protein in 50 μl × 1000).
For the in vitro mitochondrial ATP Synthase activity 
assay, 50 µg/50 µl of protein lysates isolated from MDA-
231 and MDA-468 cells were directly incubated in the 
presence or absence of CADD522 (0~2 µM), and ATP 
Synthase Activity was measured. Relative activity is 
expressed as changes in absorbance or Ratio per minute 
([ΔAbsorbance or ΔRatio]/Δmin/50 μg protein ×1000). 
Ratio indicates relative value to the absorbance at 0 min.
Mitochondrial membrane potential (MMP) 
(∆Ψm)
The changes in MMP were evaluated using a 
cationic fluorescent indicator (JC-1; Molecular Probes, 
Eugene, OR, USA), which aggregates in polarized 
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mitochondria (red fluorescence), indicating high or normal 
MMP and remains in monomeric form in the cytoplasm 
when mitochondria are depolarized (green fluorescence), 
indicated low MMP. Cells in 96 well plates were incubated 
in the growth medium containing 1 mg/mL JC-1 dye for 
30 minutes at 37°C, and fluorescence was acquired at 
488/525 nm (ex/em) for JC-1 monomers and 488/590 nm 
(ex/em) for J-aggregates using a fluorescence microplate 
reader (BioTek). MMP (∆Ψm) was expressed as the ratio 
of red to green fluorescence intensity. JC-1 aggregation 
is a survival marker and JC-1 monomer is a cell death 
indicator.
Alternatively, we assessed the MMP using 
tetramethylrhodamine methyl ester (TMRM), a cell-
permeant, cationic, red fluorescent dye that accumulates 
in active (healthy and functioning) mitochondria with 
intact membrane potentials. Upon loss of the MMP, 
TMRM accumulation ceases and the signal disappears. 
Cells were incubated with TMRM (50 µM) for 10 min and 
fluorescence intensity was measured at 561/590 nm (ex/
em) in a microplate reader (BioTek). Carbonylcyanide-3-
chlorophenylhydrazone (CCCP, 50 µM), a mitochondrial 
uncoupler, was used as a positive control for the MMP 
reduction.
Measurement of mitochondrial mass
Mitochondrial mass was determined with the 
MitoTracker Green FM (Life Technologies) dye that 
is non-fluorescent in aqueous solutions, but becomes 
fluorescent upon accumulating in the mitochondrial lipid 
environment regardless of membrane potential [113]. Cells 
plated in 96 well plates were treated with CADD522 in 
phenol red–free growth medium for 24 hr. Cells were 
washed with HBSS, and then incubated with Mitotracker 
Green as per manufacturer’s protocol. Green fluorescence 
was determined at 490/516 nm (ex/em) in a fluorescence 
microplate reader (BioTek).
Complex I (NADH dehydrogenase) activity 
assays
Quantitative measurement of Complex I activity 
was performed with a commercially available Complex 
I Enzyme Activity Microplate Assay Kit (Abcam, 
ab109721) as per manufacturer’s instruction. Cell 
conditions for measuring Complex I activity were the 
same as described for measuring the mitochondrial 
ATP synthase activity. The activity was determined by 
measuring the oxidation of NADH to NAD+ with the 
simultaneous reduction of a dye (increased absorbance at 
450 nm) for 30~60 min. Protein concentration was used to 
normalize activity (∆Absorbance /∆min/µg protein in 50 
µl × 1000), which was linear between 10–400 µg protein. 
Data are presented in arbitrary units (au).
Cellular thermal shift assay (CETSA)
CETSA [62, 63] was performed with MDA-MB-231 
cells cultured in DMEM medium supplemented with 10% 
FBS. For an initial determination of the melting profile 
of α- or β-F1-ATP synthase subunits (α-F1 and β-F1), 
fresh cell lysate prepared in non-denaturing buffer was 
dispensed into a 96-well PCR plate in the above medium 
(approx. 6,000 cells/50 µl/well), and then was subjected to 
temperature gradient (38~60°C) for 10 min. Subsequently, 
centrifugation was performed at 14.000 rpm to sediment 
the unstable protein content. Supernatant was collected 
and SDS-PAGE gel was run, and immunoblot analysis was 
performed for α-F1 and β-F1 using corresponding primary 
antibodies. Band intensity was quantified on C-Digit Blot 
Scanner (LI-COR Biosciences, Lincoln, NE, USA), and 
subsequently Tagg(50) and Tagg(75) values (temperatures at 
which 50% and 75% of the initial protein was reduced, 
respectively) were calculated for each protein. In a 
subsequent run, fresh lysates of MDA-MB-231 cells were 
treated at various doses of CADD522 and vehicle control 
(0.1% DMSO) for 1 hr. Samples were then subjected to 
heat shock at Tagg(75) for 10 min, and unstable protein 
was removed by centrifugation step. Following an 
immunoblotting step, bands of stable target proteins were 
quantified, normalized to loading control and plotted using 
GraphPad Prism software. EC50 values of CADD522 with 
each target protein were calculated.
Differential scanning fluorimetry (DSF)
Recombinant human mitochondrial ATP synthase 
subunit α (α-F1-ATP synthase) and β (β-F1-ATP synthase) 
were purchased from CusaBio (Houston, TX, USA). Binding 
of CADD522 to α or β subunit was examined experimentally 
using DSF, which evaluates changes in the target protein 
melting temperature (Tm) due to interactions with the test 
compound [64, 114, 115]. SYPRO orange (Thermo Fisher 
Scientific) diluted 1:1000 in 10 mM HEPES, 150 mM NaCl 
(pH 7.5), and 1.5 µM recombinant proteins were added to 
96-well PCR plates. Then 0 to 200 µM CADD522 dissolved 
in DMSO (1% final DMSO concentration) was added, the 
plates were mixed, sealed, centrifuged at 1,000 rpm for 1 
min, and melting curve analysis was performed using an 
Applied Biosystems StepOne real-time PCR instrument. The 
midpoint was determined from the first derivative curve, 
and the corresponding temperature (Tm) was taken from the 
midpoint.
Hydrogen peroxide (H2O2)-ROS levels
Hydrogen peroxide (H2O2)-ROS levels were 
determined using a commercial kit (ROS-Glo™ H2O2 Assay 
kit, Promega), a luminescence-based assay that measures 
the level of H2O2 directly in cell culture. Luciferin and 
recombinant Luciferase in the kit generate a luminescent 
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signal that is proportional to H2O2 concentration. Cells 
plated in 96 Black (or white) well plates and incubated in 
10% DMEM (Complete M) were treated with CADD522 
with or without H2O2 (25 µM) for 6~24 hr. After exposure to 
H2O2, 50 µl of media samples were transferred to a separate 
plate to combine with an equal volume of ROS-Glo™ 
Detection Solution, and the ROS-Glo™ H2O2 Assay was 
performed as per manufacturer’s instruction (the non-lytic 
assay). H2O2 substrate provided by the kit was exogenously 
added for ROS generation.
Cell growth and survival assay
Cell growth was determined by crystal violet 
staining. Cells were plated on 96-well (30,000 cells/well) 
or 24-well plates (50,000 cells/well). After CADD522 
treatment, cells were incubated for 24~72 hr. Cells were 
stained with crystal violet (0.5% in methanol: acetic acid = 
3:1) and washed with PBS. Crystal violet was solubilized 
in DMSO and measured in a microplate reader at 592 nm. 
For tumorsphere growth, single cell suspensions (100,000 
cells/well) were plated in 6-well ultra-low attachment 
plates (Corning) with 5 ml of DMEM supplemented with 
10% serum. CADD522 (50 µM) was added at the day of 
the plating or 4 days after plating. Tumorspheres were 
photographed and counted at the final day of the assay 
(day 7). Spheres were counted from 9 fields per well 
and averaged from triplicate. For clonogenic survival 
determination, cells were plated on 6-well plates (200 
~500 cells/well). After CADD522 (50 µM) treatment, cells 
were incubated for 2~3 weeks without changing media. 
Colonies were fixed in Methanol-Acetic Acid solution 
(3:1) and stained with crystal violet (0.5%). After washing, 
colonies were photographed and counted.
Quantitative real time-RT-PCR (Q-RT-PCR)
Total RNA was extracted using TRIzol (Life 
Technologies). One μg of total RNA was reverse transcribed 
with oligo-(dT) primer using the SuperScript first-strand 
synthesis system (Invitrogen) to synthesize cDNA. One μl of 
each cDNA was used for real-time RT-PCR using QuantiFast 
SYBR Green PCR Kit (Promega). mRNA expression of gene 
of interest relative to β-actin was calculated based on the 
threshold cycle (Ct) as 2
-∆(∆Ct) method. Primer sequences are 
listed in Supplementary Table 4.
Statistical analysis
Results from cell culture assays are expressed as 
mean ± SD from at least three independent experiments. 
Comparisons of quantitative data between two groups 
were analyzed using the two-tailed Student’s t-test. For 
the in vivo study, data are expressed as mean ± SE. All 
multiple comparisons were followed by Tukey’s post-hoc 
adjustment following ANOVA and Mann-Whitney non-
parametrical tests. All statistical analyses were conducted 
using STATA version 14 (STATA Inc., College Station, TX, 
USA). P values less than 0.05 were considered significant.
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